First quarter 2016 HIFU Division revenue increased 102% year-over-year 37% growth in HIFU treatment driven revenues in Q1 2016 compared to Q1 2015 €0.7 million operating profit, €1.4 million net income in first quarter 2016 510(k) application for Focal One submitted to FDA LYON, France , May 18,

Conference Call and Webcast Scheduled for 8:30 a.m. ET

Company to Participate in Two Plenary Sessions and Five Poster Sessions Ablatherm Treatments Performed During "L.A. Live" Pre-AUA Symposium at USC LYON, France , May 04, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that it will

LYON, France , April 28, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that The Brazilian Health Surveillance Agency (Anvisa) has approved Focal One for sale in Brazil . Marc Oczachowski , EDAP TMS Chief Executive Officer,

LYON, France , April 25, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the sale and installation of Ablatherm Robotic HIFU at Houston Methodist Hospital , Houston, Texas . The hospital is the first location in Texas to install

Leading HIFU Mobilizer Begins Operation on Ablatherm® Robotic HIFU Following First Quarter 2016 Purchase

Positions EDAP to Accelerate U.S. Sales and Marketing Expansion for HIFU Strengthens Financial Resources to Grow Global Operations LYON, France , April 14, 2016 (GLOBE NEWSWIRE) --  EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, announced the closing of its previously

LYON, France , April 07, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, announced that it has entered into definitive agreements with certain institutional investors for a registered direct placement of 3,283,284 ordinary shares in the form of

LYON, France , April 06, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for the clearance of its next generation HIFU device: the Focal One ® .

Obtained FDA clearance in November 2015 for Ablatherm Robotic HIFU; Fourth quarter 2015 HIFU Division revenues tripled over fourth quarter 2014; Overall fourth quarter 2015 revenues increased 82% over 2014 to EUR 11.8 million ( USD 12.8 million ); Solid cash position of EUR 14.6 million ( USD 15.8